Temporary pause in US shipments from Sun Pharma's plant in Mohali

It implies that company has to take corrective action before releasing further batches to the US

Sohini Das Mumbai
Sun Pharma

Listen to This Article

United States Food and Drug Administration (USFDA) has asked Sun Pharmaceutical Industries to take certain corrective actions at the Mohali facility before releasing further final product batches into the US, the company said in the notification to the BSE on Sunday.
"The company is taking the required corrective steps, but there will be a temporary pause in the release of batches from Mohali until USFDA-mandated measures are implemented," Sun Pharma said.

US shipments from Mohali will resume once these measures are in place, it added.

Corrective actions include retaining an independent current good manufacturing practice (CGMP) expert to conduct batch certifications of drugs manufactured at the Mohali facility.

Sun Pharma got a consent decree correspondence/non-compliance letter from the US Food and Drug Administration for Mohali Facility.
The consent decree sets a strict timetable and requirements for the firm to ensure it obtains compliance with current good manufacturing practice (CGMP) requirements under the Federal Food, Drug, and Cosmetics Act (FD&C Act).

The facility at Mohali, Punjab was inspected from August 3 to August 12, 2022, and the USFDA classified the inspection as 'Official Action Indicated' (OAI).
“We now wish to inform you that the Company has received a letter titled 'Consent Decree correspondence/non-compliance letter’ from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US,” Sun Pharma said.

Also Read

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Sun Pharma extends gains post September quarter earnings; up 6% in two days

Online cosmetics retailer Nykaa's Q2 net more than doubles to Rs 5.2 cr

Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

India business to boost pharma, after US sales prove to be a mixed bag

Muthoot Microfin expects 25-30% growth in loan disbursals in FY23

30% of our sales could come from EVs in FY24: MG Motor India President

Kia focuses on utility vehicle segment in India for long-term growth

Banking on good monsoon for a better 2nd half in smaller towns: Wipro

Expect stable cash flows and earnings in FY24, Adani tells banks

The plant was under OAI status already, which is expected to impact approvals pending for products, but does not impact the current business from the facility. Last November, Sun Pharma had said that the OAI status is not likely to have any material adverse impact on the current business from the facility. It continued to manufacture and distribute existing products for the US market.

First Published: Apr 23 2023 | 2:47 PM IST

Explore News